MEDICAL DIRECTOR RARE BLOOD DISORDERS
Boston, MA 02114
Location: Boston, MA
Company: Top BioPharma Company
Compensation: $140,000 to $270,000 Base + Bonus + Stocks + Amazing Benefits
Contact: Ken Kupersmith - [email protected]
1.Determine/refine the US Cold Agglutinin Disease (CAD) Medical Affairs strategy and create the vision of excellence in Medical Affairs for the future.
2.Serve as the internal expert for CAD and Cablivi and supports the field-based U.S. medical affairs team
3.Develops strategies for and implements national medical advisory boards
4.Execution of the strategic U.S. investigator-sponsored study program
5.Develops the CAD specific U.S. scientific communication and publication strategies
6.Develop systems, processes and standards to ensure the creation and effective operation of the new Medical Affairs function.
7.Support pricing and reimbursement efforts in alignment with Market Access lead.
8.Work closely and guide the Medial Review and Promotional Review Committees
9.Support the implementation of the Global Publication Plan, with key focus in driving the strategy and implementation in NA, ensuring an efficient and effective communication of the available Sutimlimab data.
10.Work closely with R&D and Commercial to support pre- and post-launch activities.
11.Develop and maintain relationships with a wide array of external stakeholders, including relevant advocacy groups, KOLs and advisory Board members and others in the clinical and scientific community, plus where appropriate, key decision makers in Payer organizations, etc.
12.Contribute to the clinical strategy, and execute all Phase IIIb and IV clinical programs and any other late-phase research activities (i.e., registries).
1.MD qualification preferred and a solid track record of achievement in Medical Affairs in the biotech/pharma industry.
2.Ideally have worked in the field of orphan diseases; Hematology experience would be advantageous.
3.Experience in clinical trial design, especially phase III-IV
4.Able to make complex science understandable for a non-scientific audience.
5.MD or MD PhD preferred
6.MBA would be a plus.